more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Rare Disease Co. Presents Positive Phase 2 KP1077 Data

Research Report
  ()
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.

Pharma Co. Secures $650M Strategic Financing

Research Report
  ()
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.

Pharma Stock Focuses on Successful Ensifentrine Launch

Research Report
  ()
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.

Pharma Stock Nears FDA Approval

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. is at the final stretch for its FDA approval.

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.

Biopharma's New Drug for COPD Likely to be Approved

Research Report
  ()
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.

PDUFA Date Coming Up for U.K. Biopharma

Research Report
  ()
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.

Analyst Says Pharma Co. Has No True Competitor

Research Report
  ()
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.

LA Biotech's Lower Revenue Will Be Short Lived

Research Report
  ()
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.

Biotech Co.'s Target Price Significantly Higher Than Current

Research Report
  ()
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.

NY Biotech Has Potentially Game Changing Anxiety Therapy

Research Report
  ()
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.

Leadership Cuts Won't Slow This Biotech

Research Report
  ()
While three executive officers have been cut from Kronos Bio Inc., it is still a Buy, according to an H.C. Wainwright & Co. report.

Pharma Co. Primed for Future Business

Research Report
  ()
Analysts at Research Capital believe that Knight Therapeutics Inc. is primed to conduct future business development.

Healthcare Co. Exceeds Expectations in Performance

Research Report
  ()
Sensus Healthcare Inc. released fourth-quarter financials that surpassed expectations, according to an H.C. Wainwright & Co. research note.

Biotech Co.'s Sales Could Grow To US$310 Million in 2028

Research Report
  ()
Biotech Valneva SE announced that it had dosed the first participant in a Phase 2 pediatric trial evaluating its chikungunya vaccine candidate, according to an H.C. Wainwright & Co. report.

Boston Biotech Could Have Blockbuster Sales

Research Report
  ()
Tango Therapeutics may have "blockbuster potential," noted an H.C. Wainwright & Co. report.

California-Based Pharma Co.'s Progress Offers Upside

Research Report
  ()
While H.C. Wainwright & Co. lowered their price target, they still see upside for this pharmaceutical company.

Co.'s Breast Cancer Therapy Shows Encouraging Activity

Research Report
  ()
BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.

Biotech Secures Additional Funding, Extending Cash Runway

Research Report
  ()
Recently, Vera Therapeutics Inc. announced it had further strengthened its balance sheet by drawing down US$25 million in debt, bringing total cash reserves to US$159.9 million, noted H.C. Wainwright & Co.

Biotech Bolsters ADC Pipeline Through Atreca Asset Buy

Research Report
  ()
Biotech Immunome Inc. recently announced a purchase agreement with Altreca, noted Wedbush.

US Biotech's Anti-Fungal Wins European Approvals

Research Report
  ()
Recently, Cidara Therapeutics Inc. secured European Commission (EC) approval for its lead anti-fungal candidate Rezafungin to treat invasive candidiasis infections in adults, noted H.C. Wainwright & Co.

Biotech Co. Reports Encouraging ALS Data but FDA Wants More

Research Report
  ()
Salt Lake City-based Clene Inc. reported both encouraging clinical data and a regulatory setback for its ALS drug candidate CNM-Au8, reported Roth MKM.

Pharma Co. May Have Accelerated FDA Approval in 2024

Research Report
  ()
TRACON Pharmaceuticals Inc. provided an update on enrollment progress for their ongoing Phase 2 ENVASARC clinical trial testing the drug envafolimab to treat sarcoma, reported H.C. Wainwright & Co.

Bioscience Co. Expands Collaboration

Research Report
  ()
This bioscience company's price target implies 680% upside, according to a Roth MKM report.

Texas Biotech Advances Lead Candidate in Resistant AML

Research Report
  ()
Recently, Texas-based biotech Bio-Path Holdings Inc. announced it had completed the first safety cohort of a Phase 1/1b trial evaluating the developmental drug BP1002 in acute myeloid leukemia (AML). Read on to see what one Roth analyst has to say about the company's stock.

Showing Results: 1 to 25 of 25